What is it about?
Objective Medical management of primary hyperparathyroidism (PHPT) is important in patients for whom surgery is inappropriate. We aimed to describe clinical profiles of adults with PHPT receiving cinacalcet.
Featured Image
Why is it important?
Conclusions Reductions in calcium levels of ≥1 mg/dl was observed in 60% of patients 12 months after initiation of cinacalcet, without notable safety concerns.
Perspectives
Correct use of treatment for the right patient at the right time
Peter Schwarz
Region Hovedstaden
Read the Original
This page is a summary of: The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice, European Journal of Endocrinology, December 2014, Bioscientifica,
DOI: 10.1530/eje-14-0355.
You can read the full text:
Contributors
The following have contributed to this page
